Unexplained Hoarseness of Voice after Radioactive Iodine Therapy; A Rare Complication
Journal Title: Open Access Journal of Endocrinology - Year 2017, Vol 1, Issue 2
Abstract
Hoarseness of voice is extremely rare after radioactive iodine therapy for Graves’s disease. Here we report a case of 29 year old lady who received one dose of 15mCi of RAI. After one day she presented with severe hoarseness of voice, severe pain in neck and some sore throat. The pain and sore throat resolved after a week with NSAID therapy but her hoarseness of voice persisted. She underwent direct laryngoscopy twice but showed no abnormality in vocal cord. Later on her voice started to improve and by about 6 months largely recovered. This case is in addition to few rare case reports in medical literature in which RAI caused hoarseness of voice.
Authors and Affiliations
Tauseef Ahmad
Agranulocytosis: A Rare Complication and Management Paradox
Introduction: Thyroid disorders are common disorders seen around the globe. The prevalence of thyroid disorders in India is approximately 5-10%, more common in females and hypothyroidism being more common than hypothyroi...
Diabetes, Cinnamon and Green tea
Diabetes is a metabolic disease with many important complications. Recently role of herbal medicine in combination with chemicals is under consideration, especially because of few adverse effect of these medications, the...
Pseudohypoparathyroidism 1a – A New Case Report
Patients with Pseudohypoparathyroidism 1a (PHP-1a) have a typical phenotype, described for the first time by Albright, and therefore called Albright’s Hereditary Osteodistrophy (AHO). It is characterized by a round face,...
Pioglitazone: An Ongoing Misery in the Developing Countries to Which I can’t be Pragmatic!
In 2014, I've published an article warning against the widespread usage of pioglitazone in the developing countries though it has been banned or heavily restricted in all developed countries due to its proved causation w...
Unusual Association of Two Germline Rearrangements in CDC73/HRPT2 Gene: Complexity of Clinical Counseling in the Age of Genomic Medicine
Background: Primary hyperparathyroidism is a phenotype shared by several hereditary endocrine and non-endocrine cancer predisposition syndromes caused by heterozygous germline mutations deactivating tumor suppressor gene...